Vitreoretinal Technologies
Vitreoretinal Technologies develops therapeutic compounds to treat vitreoretinal eye diseases and surgical complications. The company is an ophthalmic biopharmaceutical developer focused on drug compounds such as Vitreosolve, used for vitreous liquefaction prior to vitrectomy and for diabetic retinopathy, and Neurosolve, aimed at glaucoma and retinal degeneration. It operates as a B2B biopharma company working with clinicians, surgical centers, and distributors to commercialize ophthalmic therapeutics. The pipeline targets diabetic retinopathy, age-related macular degeneration, glaucoma, and retinitis pigmentosa, supporting both pre-surgical applications and disease-modifying treatments.
Vitreoretinal Technologies
Vitreoretinal Technologies develops therapeutic compounds to treat vitreoretinal eye diseases and surgical complications. The company is an ophthalmic biopharmaceutical developer focused on drug compounds such as Vitreosolve, used for vitreous liquefaction prior to vitrectomy and for diabetic retinopathy, and Neurosolve, aimed at glaucoma and retinal degeneration. It operates as a B2B biopharma company working with clinicians, surgical centers, and distributors to commercialize ophthalmic therapeutics. The pipeline targets diabetic retinopathy, age-related macular degeneration, glaucoma, and retinitis pigmentosa, supporting both pre-surgical applications and disease-modifying treatments.
TL;DR
Sector: Ophthalmic biopharmaceuticals (vitreoretinal)
Lead executive (reported): Hampar Karageozian — listed as having served as CEO
Products / pipeline (reported): Therapeutic compounds for vitreous liquefaction and retinal diseases (e.g., Vitreosolve, Neurosolve)
Founded: 2017
Employee count (reported): ~40
Company Overview
Problem Domain
Vitreoretinal diseases and surgical complications affecting vision
Founded
2017
Industry
Biotechnology